Dr. DeRossett is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5375 Medpace Way
Cincinnati, OH 45227Phone+1 513-579-9911Fax+1 513-579-0444
Summary
- Dr. Sarah DeRossett is a Neurology specialist based in Cincinnati, OH. She completed her medical education at Emory University School of Medicine in 1987, followed by an internship in Internal Medicine and a residency in Neurology at Johns Hopkins University. Dr. DeRossett is currently a Senior Medical Director at Medpace. She has published multiple research articles primarily focusing on antiepileptic drugs, with several studies addressing the efficacy, safety, and tolerability of ezogabine/retigabine, and her work has been cited in the field numerous times.
Education & Training
Johns Hopkins UniversityResidency, Neurology, 1988 - 1991
Emory University School of MedicineInternship, Internal Medicine, 1987 - 1988- Emory University School of MedicineClass of 1987
Certifications & Licensure
GA State Medical License 1991 - 2025
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 8 citationsEfficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset sei...Holger Lerche, Jerzy Daniluk, Narinder Lotay, Sarah DeRossett, Suzanne Edwards
Seizure. 2015-08-01 - 5 citationsAdjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation o...Martin J. Brodie, Jacqueline A. French, Susan A. McDonald, Wen-Jene Lee, Bryan Adams
Epilepsy Research. 2014-07-01 - 7 citationsA novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development.Rajesh Sachdeo, Arnaud Partiot, Victor Biton, William E. Rosenfeld, Virinder Nohria
International Journal of Clinical Pharmacology and Therapeutics. 2014-06-01
Press Mentions
Safety of Retigabine in Adults with Partial-Onset Seizures After Long-Term Exposure: Focus on Unexpected Ophthalmological and Dermatological EventsNovember 12th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
